High Immunity and Low Mortality After Omicron and Mass Event in Cameroon Despite Low Vaccination

Aim: We evaluated changes in anti-SARS-CoV-2 antibodies, mortality and vaccination status in Cameroon between August 2021 and September 2022 to begin describing the evolution of the pandemic in Africa.

Setting: The study was conducted across Cameroon's 10 regional capitals, between 2021 and 2022 as the country hosted a mass gathering.

Methods: We conducted a cross-sectional population-based survey in 2022, including SARS-CoV-2 seroprevalence testing and retrospective mortality estimation using two-stage cluster sampling. We estimated and compared seroprevalence and crude mortality rates (CMR) to a survey conducted in 2021 using the same methodology.

Results: We performed serologic testing on 8400 individuals and collected mortality data from 22 314 individuals. Approximately 5% in each survey reported SARS-CoV-2-vaccination. Rapid diagnostic test-based seroprevalence increased from 11.2% (95% confidence interval [CI]: 10-12.5) to 59.8% (95% CI: 58.3-61.2) between 2021 and 2022, despite no increase in the proportion vaccinated. The CMR decreased from 0.17 to 0.06 deaths per 10 000 persons per day between 2021 and 2022. In 2022, no deaths were reportedly attributable to COVID-19 as compared to 17 deaths in 2021.

Conclusion: Over a 12-month period encompassing two waves of omicron variant SARS-CoV-2 and a mass gathering, SARS-CoV-2 seropositivity in Cameroon approached 60%, and deaths declined despite low vaccination coverage.

Contribution: This study challenges the assumption that high immunisation coverage is the sole determinant of epidemic control in the African context and encourages policymakers to increasingly rely on local research when designing response strategies for more effective outbreak management.

References

Callow K . Effect of specific humoral immunity and some non-specific factors on resistance of volunteers to respiratory coronavirus infection. J Hyg (Lond). 1985; 95(1):173-89. PMC: 2129501. DOI: 10.1017/s0022172400062410. View

Wiegand R, Deng Y, Deng X, Lee A, Meyer 3rd W, Letovsky S . Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022. Lancet Reg Health Am. 2022; 18:100403. PMC: 9716971. DOI: 10.1016/j.lana.2022.100403. View

Lewis H, Ware H, Whelan M, Subissi L, Li Z, Ma X . SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021. BMJ Glob Health. 2022; 7(8). PMC: 9402450. DOI: 10.1136/bmjgh-2022-008793. View

Peeling R, Olliaro P . The time to do serosurveys for COVID-19 is now. Lancet Respir Med. 2020; 8(9):836-838. PMC: 7380934. DOI: 10.1016/S2213-2600(20)30313-1. View

Bond K, Nicholson S, Lim S, Karapanagiotidis T, Williams E, Johnson D . Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. J Infect Dis. 2020; 222(8):1280-1288. PMC: 7454699. DOI: 10.1093/infdis/jiaa467. View

Callow K, Parry H, Sergeant M, Tyrrell D . The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990; 105(2):435-46. PMC: 2271881. DOI: 10.1017/s0950268800048019. View

Bergeri I, Whelan M, Ware H, Subissi L, Nardone A, Lewis H . Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS Med. 2022; 19(11):e1004107. PMC: 9648705. DOI: 10.1371/journal.pmed.1004107. View

Salyer S, Maeda J, Sembuche S, Kebede Y, Tshangela A, Moussif M . The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. Lancet. 2021; 397(10281):1265-1275. PMC: 8046510. DOI: 10.1016/S0140-6736(21)00632-2. View

Byambasuren O, Dobler C, Bell K, Rojas D, Clark J, McLaws M . Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLoS One. 2021; 16(4):e0248946. PMC: 8018669. DOI: 10.1371/journal.pone.0248946. View

10.

Ines R, Gabriela H, Paula C, Magdalena T, Jimena A, Salome K . Performance of Elecsys Anti-SARS CoV-2 (Roche) and VIDAS Anti-SARS CoV-2 (Biomérieux) for SARS-CoV-2 Nucleocapsid and Spike Protein Antibody Detection. EJIFCC. 2022; 33(2):159-165. PMC: 9562483. View

11.

Berhan Y . Will Africa be Devastated by Covid-19 as Many Predicted? Perspective and Prospective. Ethiop J Health Sci. 2020; 30(3):459-467. PMC: 7445943. DOI: 10.4314/ejhs.v30i3.17. View

12.

Dopico X, Ols S, Lore K, Karlsson Hedestam G . Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med. 2021; 291(1):32-50. PMC: 8447342. DOI: 10.1111/joim.13372. View

13.

Simons E, Nikolay B, Ouedraogo P, Pasquier E, Tiemeni C, Adjaho I . Seroprevalence of SARS-CoV-2 antibodies and retrospective mortality in two African settings: Lubumbashi, Democratic Republic of the Congo and Abidjan, Côte d'Ivoire. PLOS Glob Public Health. 2023; 3(6):e0001457. PMC: 10249894. DOI: 10.1371/journal.pgph.0001457. View

14.

Fanidi A, Jouven X, Gaye B . Strategies to control COVID-19 and future pandemics in Africa and around the globe. Eur Heart J. 2020; 41(41):3973-3975. PMC: 7184329. DOI: 10.1093/eurheartj/ehaa278. View

15.

OSullivan T, Sun J, Lanier L . Natural Killer Cell Memory. Immunity. 2015; 43(4):634-45. PMC: 4621966. DOI: 10.1016/j.immuni.2015.09.013. View

16.

Xu A, Hong B, Lou F, Wang S, Li W, Shafqat A . Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention. MedComm (2020). 2022; 3(3):e172. PMC: 9380698. DOI: 10.1002/mco2.172. View

17.

Guedez-Lopez G, Alguacil-Guillen M, Gonzalez-Donapetry P, Bloise I, Tornero-Marin C, Gonzalez-Garcia J . Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2. Eur J Clin Microbiol Infect Dis. 2020; 39(12):2289-2297. PMC: 7431115. DOI: 10.1007/s10096-020-04010-7. View

18.

ODriscoll M, Ribeiro Dos Santos G, Wang L, Cummings D, Azman A, Paireau J . Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020; 590(7844):140-145. DOI: 10.1038/s41586-020-2918-0. View

19.

Manathunga S, Abeyagunawardena I, Dharmaratne S . A comparison of transmissibility of SARS-CoV-2 variants of concern. Virol J. 2023; 20(1):59. PMC: 10067514. DOI: 10.1186/s12985-023-02018-x. View

20.

Esso L, Epee E, Bilounga C, Abah A, Hamadou A, Dibongue E . Cameroon's bold response to the COVID-19 pandemic during the first and second waves. Lancet Infect Dis. 2021; 21(8):1064-1065. PMC: 8318523. DOI: 10.1016/S1473-3099(21)00388-1. View